← Azimuth Daily
Capturing data…
Capturing data…
FRI, 25 SEPT · 76 ITEMS
AP, Washington Times, STAT News + 7 more · Science & Medicine
10 outletsFraming varies: Most centre-leaning sources report the panel vote neutrally, while right-leaning outlets like Newsmax and Washington Examiner emphasize regulatory hurdles or skepticism about accessibility, and an opinion piece argues Washington is blocking patient access.
Grail's blood test, which scans for DNA fragments shed by multiple cancer types in a single blood draw, faced a pivotal review. The panel voted to endorse the test's benefits, moving it closer to full FDA approval — a landmark step for multi-cancer early detection technology, which has not yet been widely approved in the U.S.
The coverage is solid, based on multiple reputable outlets (AP, NPR, Scientific American) reporting directly on the FDA advisory panel's vote and the agency's briefing documents. The primary source is the FDA panel proceeding; the reporting accurately reflects that the panel endorsed the test's benefits without granting final approval.
The FDA advisory panel review and vote occurred on September 23–24, 2026, making this genuinely new coverage of a current regulatory event.
On September 24, 2026, we covered the PATHFINDER 2 trial, which reported on the safety and performance of the same multi-cancer early-detection blood test — a key study underlying the FDA review.